HOME >> BIOLOGY >> NEWS
Scientists follow familiar TRAIL to new cancer therapy

A new study identifies a combination therapy that may sensitize human cancer cells to a promising treatment currently being used in clinical trials. The research, published in the July issue of the journal Cancer Cell, published by Cell Press, provides a pharmacological method for enhancing the potency and effectiveness of a tumor necrosis factor (TNF) death receptor ligand against a variety of human cancers.

Potency and lack of toxicity to normal tissues make activation of TNF-a-related apoptosis-inducing ligand (TRAIL) death receptor signaling an attractive and exciting target for cancer therapy, and it is currently being tested in clinical trials. However, most cancer cells have defects in their ability to die via a cell death pathway called apoptosis, and unfortunately, TRAIL therapy is not effective in cells that have certain defects in apoptotic pathways. Dr. Wafik S. El-Deiry from the University of Pennsylvania School of Medicine and colleagues designed a series of studies to gain a better understanding of TRAIL-associated cell signaling pathways in cancer cells and to look for ways to pharmacologically optimize TRAIL therapy.

Dr. El-Deirys group had previously established that c-Myc is a key mediator of TRAIL-induced apoptosis and that cancer cells lacking c-Myc and a functional apoptotic pathway were resistant to TRAIL. In the current study, the researchers demonstrated that expression of c-Myc in TRAIL-resistant human colon cancer cells sensitized the cells to TRAIL, even when the cells had intrinsic apoptotic defects. The researchers observed that TRAIL induced expression of two potent antiapoptotic molecules, Mcl-1 and cIAP2, and that c-Myc repressed both molecules.

The researchers also discovered that the multikinase inhibitor sorafenib prevented TRAIL-mediated induction of Mcl-1 and cIAP2, and although it had little effect on the killing of TRAIL-resistant cells when administered alone, combination with TRAIL caused
'"/>

Contact: Erin Doonan
edoonan@cell.com
617-397-2802
Cell Press
9-Jul-2007


Page: 1 2

Related biology news :

1. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
2. Scientists prove that disputed Korean stem cell line comes from an unfertilized egg and not cloning
3. Scientists move closer to bio-engineered bladders
4. Scientists find stem cell switch
5. Scientists discover new way to study nanostructures
6. Scientists a step closer to understanding how anaesthetics work in the brain
7. Scientists to make news at Computational Biology Conference
8. Accident-prone? Scientists link brain function to knee injuries
9. Scientists take next step in understanding potential target for ovarian cancer treatment
10. Scientists find brown fat master switch
11. Scientists identify 2 distinct Parkinsons networks

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski to lead ... near term focus on Type 2 diabetes and associated comorbidities. , Justin brings ... areas and classes. As Chief Commercial Officer, Justin will lead Better Therapeutics’ ...
(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced the first in ... on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional content and flavor ... live on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition ...
(Date:7/1/2020)... (PRWEB) , ... July 01, 2020 , ... ... building awareness and solutions for glioblastoma—the most common and aggressive adult brain cancer—announced ... Haile, JD, PhD. Senior Fellows are charged with supporting the organization’s initiatives and ...
Breaking Biology News(10 mins):
(Date:8/7/2020)... ... August 06, 2020 , ... ... announces it has closed on the purchase of greenfield for a new, expanded ... and includes over 21 acres in the initial acquisition, with an option to ...
(Date:7/31/2020)... ... , ... R3 Stem Cell International is now offering patients the opportunity to ... total, patients may choose which extremities they would like treated. , Several studies have ... 2016). At R3 International, umbilical cord tissue is obtained from a lab with a ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... that can combine up to three different materials for use with CRM, neurostimulation, ... up to three materials to meet specific design requirements, performance, and cost criteria; ...
(Date:7/31/2020)... ... July 29, 2020 , ... The SDX® ... in 16 countries, has reached its 20th anniversary of worldwide use. Introduced in ... at top universities including University of Pennsylvania, University of Michigan, University of Maryland, ...
Breaking Biology Technology:
Cached News: